latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/leveraged-loan-news/horizon-pharma-inks-commitment-letter-for-900m-leveraged-loan-backing-hyperion-buy content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Horizon Pharma inks commitment letter for $900M leveraged loan backing Hyperion buy

Leveraged Loan Fund Assets Shrink Anew As Retail Investors Eye High Yield

Video: CLOs feel pinch from lumpy loan supply

Retail investors withdraw $2.57B from US high yield bond funds

Despite investor appetite, April European leveraged loan issuance slumps to €2.5B


Horizon Pharma inks commitment letter for $900M leveraged loan backing Hyperion buy

Horizon Pharma disclosed that it has obtained a commitment letter from Citigroup and Jefferies providing $900 million of senior secured term loans in connection with the company’s planned $940 million acquisition of Hyperion Therapeutics.

Under the terms of the acquisition, Horizon Pharma will acquire the outstanding shares of Hyperion for $46 per share. The acquisition, which has been approved by both companies’ boards of directors, is expected to close in the second quarter.

Proceeds from the new deal are also earmarked to repay Horizon’s $300 million senior secured credit facility it obtained in 2014 to back the company’s acquisition of Vidara Therapeutics.

Horizon Pharma is a specialty pharmaceutical maker. The Deerfield, Ill.-based company was founded in 2005. – Richard Kellerhals